Pharmacokinetic profile of fesoterodine

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 11, 2008, Pages 556-563

  Malhotra, B ^a   Guan, Z ^a   Wood, N ^b   Gandelman, K ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

5 HMT; Antimuscarinic; Fesoterodine; OAB; Pharmacokinetics

Indexed keywords

5 HYDROXYMETHYLTOLTERODINE; CYTOCHROME P450 2D6; DRUG METABOLITE; FESOTERODINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; SUSTAINED RELEASE PREPARATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; XEROSTOMIA;

EID: 56749153933     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46556     Document Type: Article

References (14)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee ofthe International Continence Society. Urology. 2003; 61: 37-49.
2. Brynne N, Stahl MM, Hallen B, Edlund PO, Palmer L, Hoglund P, Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment ofurinary bladder overactivity. Int J Clin Pharmacol Ther. 1997; 35: 287-295.
3. Cawello W, Auer S, Hammes W, Sachse R, Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch-Pharmacol. 2002; 365: R110.
4. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst H-T, Massow U, Wang J, Brodsky M. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007; 52: 1204-1212.
5. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future. 2004; 29: 715-720.
6. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. For Urol. 2006; 50: 1306-1315.
7. Nilvebrant L. The mechanism of action of tolterodine. Reviews in Contemporary Pharmacotherapy. 2000; 11: 13-27.
8. Nilvebrant L. Clinical experiences with tolterodine. Life Sci. 2001; 68: 2549-2556.
9. Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007; 178: 2488-2494.
10. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pbarmacokinet. 2001; 40: 227-235.
11. Sachse R, Cawello W, Haag MC, Horstmann R. Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine. Naunyn Schmiedebergs Arch Pharmacol. 2003a; 367: R115.
12. Sachse R, Cawello W, Hammes W, Horstmann R. Safety and pharmacokinetics of the novel bladder-selective antimuscarinic fesoterodine in populations of different ethnic origin. Proceedings of the International Continence Society. 2003b; 33: 377.
13. Toviaz (fesoterodine fumarate). Full Prescribing Information, Pfizer Inc., New York, NY, USA; 2007.
14. Tubaro A, De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline. EAU Update Series. 2004; 2: 161-169.